Rousseau et al. have also shown favorable results of CD138 targeted radioimmunotherapy: Human MDA-MB-468 TNBC bearing mice were treated with the murine anti-CD138 antibody B-B4 radiolabeled with 131I. In line with the results from our study, they observed a significant reduction of tumor growth in 131I-B-B4 treated animals compared to control, despite CD138-expression was low on MDA-MB-468 cells, and thus confirming CD138 as suitable target for TNBC therapy [20]. This evidence concerns the gene SDC1 and neoplasm.